Freeline Therapeutics Holdings plc Operating Expenses
Freeline Therapeutics Holdings plc reported Operating Expenses of $48.62 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-12-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2023-12-01
- Freeline Therapeutics Holdings plc operating expenses for the quarter ending 2023-09-30 was $12.27M, a 47.80% decline year-over-year.
- Freeline Therapeutics Holdings plc operating expenses for the quarter ending 2023-06-30 was $16.27M, a 39.51% decline year-over-year.
- Freeline Therapeutics Holdings plc operating expenses for the quarter ending 2023-03-31 was $20.08M, a 28.71% decline year-over-year.
- Freeline Therapeutics Holdings plc operating expenses for the quarter ending 2022-12-31 was $19.88M, a 42.11% decline year-over-year.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2023-09-30 | $12.27M derived: 6-K 9 month − 6-K 6 month · filed 2023-12-01 | $28.54M derived: sum of 2 quarters · filed 2023-12-01 | $48.62M 6-K · filed 2023-12-01 | $68.50M derived: sum of 4 quarters · filed 2023-12-01 |
| 2023-06-30 | $16.27M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-15 | $36.35M 6-K · filed 2023-08-15 | $56.23M derived: sum of 3 quarters · filed 2023-08-15 | $79.73M derived: sum of 4 quarters · filed 2023-12-01 |
| 2023-03-31 | $20.08M 6-K · filed 2023-05-30 | $39.96M derived: sum of 2 quarters · filed 2023-05-30 | $63.47M derived: sum of 3 quarters · filed 2023-12-01 | $90.36M derived: sum of 4 quarters · filed 2023-12-01 |
| 2022-12-31 | $19.88M derived: 20-F 12 month − 6-K 9 month · filed 2023-04-04 | $43.38M derived: sum of 2 quarters · filed 2023-12-01 | $70.28M derived: sum of 3 quarters · filed 2023-12-01 | $98.45M 20-F · filed 2023-04-04 |
| 2022-09-30 | $23.51M derived: 6-K 9 month − 6-K 6 month · filed 2023-12-01 | $50.40M derived: sum of 2 quarters · filed 2023-12-01 | $78.57M 6-K · filed 2023-12-01 | $112.90M derived: sum of 4 quarters · filed 2023-12-01 |
| 2022-06-30 | $26.89M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-15 | $55.06M 6-K · filed 2023-08-15 | $89.40M derived: sum of 3 quarters · filed 2023-08-15 | $124.69M derived: sum of 4 quarters · filed 2023-08-15 |
| 2022-03-31 | $28.17M 6-K · filed 2023-05-30 | $62.50M derived: sum of 2 quarters · filed 2023-05-30 | $97.80M derived: sum of 3 quarters · filed 2023-05-30 | $136.61M derived: sum of 4 quarters · filed 2023-05-30 |
| 2021-12-31 | $34.33M derived: 20-F 12 month − 6-K 9 month · filed 2023-04-04 | $69.63M derived: sum of 2 quarters · filed 2023-04-04 | $108.44M derived: sum of 3 quarters · filed 2023-04-04 | $142.38M 20-F · filed 2023-04-04 |
| 2021-09-30 | $35.30M derived: 6-K 9 month − 6-K 6 month · filed 2022-11-15 | $74.11M derived: sum of 2 quarters · filed 2022-11-15 | $108.05M 6-K · filed 2022-11-15 | $140.31M derived: sum of 4 quarters · filed 2023-04-04 |
| 2021-06-30 | $38.81M derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | $72.75M 6-K · filed 2022-08-09 | $105.01M derived: sum of 3 quarters · filed 2023-04-04 | $134.09M derived: sum of 4 quarters · filed 2023-04-04 |
| 2021-03-31 | $33.94M 6-K · filed 2022-05-10 | $66.20M derived: sum of 2 quarters · filed 2023-04-04 | $95.28M derived: sum of 3 quarters · filed 2023-04-04 | $115.20M derived: sum of 4 quarters · filed 2023-04-04 |
| 2020-12-31 | $32.26M derived: 20-F 12 month − 6-K 9 month · filed 2023-04-04 | $61.34M derived: sum of 2 quarters · filed 2023-04-04 | $81.26M derived: sum of 3 quarters · filed 2023-04-04 | $102.45M 20-F · filed 2023-04-04 |
| 2020-09-30 | $29.08M derived: 6-K 9 month − 6-K 6 month · filed 2021-11-09 | $49.00M derived: sum of 2 quarters · filed 2021-11-09 | $70.19M 6-K · filed 2021-11-09 | |
| 2020-06-30 | $19.92M derived: 6-K 6 month − 6-K 3 month · filed 2021-08-16 | $41.11M 6-K · filed 2021-08-16 | ||
| 2020-03-31 | $21.19M 6-K · filed 2021-05-17 | |||
| 2019-12-31 | $63.64M 20-F · filed 2022-03-31 | |||
| 2019-06-30 | $29.75M 6-K · filed 2020-10-29 | |||
| 2018-12-31 | $40.98M 20-F · filed 2021-03-31 |